* Polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis
* Arthritis mutilans
* Asymmetric peripheral arthritis or
* Spinal involvement
Active psoriatic arthritis at the time of the study enrollment
Patients must demonstrate greater than 3 swollen joints and greater than 3 tender/painful joints
Greater than 18 years of age at the time of consent
Able to start etanercept therapy per the approved product monograph
Informed consent must be provided before any study specific procedures are performed
You may not be if
Active infections at time of initiating Enbrel® therapy
Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the study medication
A malignancy, other than basal cell carcinoma of the skin or, in situ carcinoma of the cervix, within the past 5 years
Known hypersensitivity to etanercept or any of its components
Patients receiving, or who have received:
* Remicade® (infliximab) in the previous 3 months or -- Humira® (adalimumab) in the previous 3 months or
* Kineret® (anakinra) in the previous 15 days
Patients receiving or who have received etanercept
Treatment with any investigational therapy in the 30 days prior to enrollment or during the study
Active guttate, erythrodermic or pustular psoriasis at the time of screening
Presence of any significant and uncontrolled medical condition, which in the Investigator's opinion, precludes the use of etanercept as outlined in the product monograph
Sepsis or at risk of septic syndrome
Patients not available for follow-up assessment
Concerns for subject's compliance with the protocol procedures
